|
Bibliografia
Forni GL, Derchi G. Typical manifestation of acute congestive heart failure
in patients with Thalassaemia major causing diagnostic delay in the
emergency room. Eur J Heart Fail. 2003; 5(5):607-8
Hui L, Leung MP, Ha SY, Chau AKT, Cheung YF. Early detection of left
ventricular dysfunction in patients with b thalassemia major by dobutamine
stress echocardiography. Heart 2003;89:669-670
Bosi G, Crepaz R, Gamberini MR, Fortini M, Scarcia S, Bonsante E,
Pitscheider W, Vaccari M. Left ventricular remodelling, and systolic and
diastolic function in young adults with b thalassemia major: a Doppler
echocardiographic assessment and correlation with haematological data. Heart
2003;89:762-766
Kremastinos D Th, Tsiapras DP, Tsetsos GA, et al. Left ventricular diastolic
Doppler characteristics in b-thalassemia major. Circulation 1995;40(5):307
Vogel M, Anderson LJ, Holden S, Deanfield JE, Pennell DJ, Walker JM. Tissue
Doppler echocardiography in patients with thalassemia detects early
myocardial dysfunction related to myocardial iron overload. Eur Heart J
2003;24:113-119
Davies BA, O’ Sullivan C, Jarritt PH, Porter JB. Value of sequential
monitoring of left ventricular ejection fraction in the management of
thalassemia major. Blood 2004;104:263-269
Freitag MH, Vasan RS : Screening for left ventricular systolic dysfunction:
the use of B-type natriuretic peptide. Heart Fail Monit 2003; 4(2):38-44.
Anderson LJ, Holden S, Davis B, Prescott E, Charrier CC, Bunce NH, Firmin DN,
Wonke B, Porter J, Walker JM and Pennell DJ. Cardiovascular T2-star (T2*)
magnetic resonance for the early diagnosis of myocardial iron overload. Eur
Heart J 2001;22:2171-2179
Brittenham GM, Nathan DG, Olivieri NF, Pippard MJ, Weatherall. The Lancet
2003(361):183 ( letter)
St Pierre TG. Deferiprone versus desferrioxamine in thalassemia, and T2*
validation and utility. The Lancet 2003(361):182 ( letter )
Hoffbrand AV. Diagnosis of myocardial iron overload. Eur Heart J
2001;22:2140-2141
Borgna-Pignatti C,Rugolotto S, De Stefano P, et al. : Survival and disease
complications in Thalassemia Major.Ann NY Acad Sci 1998 ; 850:227
Maggio A., D’Amico G.,Morabito A.,et al.: Deferiprone versus Deferoxamine in
patients with thalassemia Major: A randomized clinical trial. Blood Cells,
Mol. and Dis.2002 ; 28 196.
Anderson L J, Wonke B, Prescott E, et al.:Comparison of effects of oral
deferiprone and subcutaneous desferrioxamine on myocardial iron
concentrations and ventricular function in beta- thalassaemia. Lancet 2002;
360: 516.
Mourad F H, Hoffbrand V, Sheikh-Taha,et al.:Comparison between
desferioxamine and combined therapy with desferrioxamine and deferiprone in
iron overloaded thalassaemia patients. Br J Haematol 2003 ; 121:187
Tsushima RG, Wickenden AD, Bouchard RA ,et al.: Modulation of iron uptake in
heart by L-type Ca2+ channels modifiers: possible implications in iron
overload. Circ. Res 1999;84:1302
Gitto E, Tau DX, Reiter RJ et al.: Individual and synergistic antioxidative
actions of melatonin; studies with vitamin E,vitamin C, glutathione and
desferioxamine in rat liver. J Pharm Pharmacol 1997 ; 53:293
Oettl K, Greilberger J, Zangger K, Haslinger E, Reibnegger G, Jurgens :
Radical-scavenging and iron-chelating properties of carvedilol an
antihypertensive drug with antioxidative activity. Biochem Pharmacol 2001
Jul 15;62(2):241-8.
Rakel R.E., Bope E.T.: Conn’s Current Therapy 2004, Elsevier Inc.
Oliveri NF,Nathan DG,Mac Millan JH et al.:Survival in medically treated
patients with homozygous B- Thalassemia .N Engl J Med 1994 ;331: 574.
Karvounis HI, Zaglavara TA, Parharidis GE, Nouskas IG, Hassapopoulou EP,
Gemitzis KD, Louridas GE : An angiotensin-converting enzyme inhibitor
improves left ventricular systolic and diastolic function in
transfusion-depedent patients with beta-thalassemia major. Am Heart J 2001
Feb ; 141(2) 281.
Koerner MM, Tenderich G, Minami K et al.: Heart transplantation for
end-stage heart failure causes by iron overload. Br J Haematol 1997;97:293
Littera R, La Nasa G, Derchi G, et al. Long-term treatment with sildenafil
in a thalassemic patient with pulmonary hypertension. Blood
2002;100:1516-1517
|
|
|
